Document Type

Report

Publication Date

3-30-2022

Comments

Submitted in partial fulfillment of the requirements for the degree of Doctor of Nursing Practice at Thomas Jefferson University, College of Nursing, Philadelphia, PA.

Abstract

The first documented cases of a patients infected with the SARS-Cov-2 (COVID-19) virus in the United States were reported in early 2020. In the time since, the COVID-19 virus has become a global pandemic with millions of cases worldwide (CDC, 2021). The World Health Organization (WHO), Surviving Sepsis Campaign, and Extracorporeal Life Support Organization (ELSO) set out to determine if the use of extracorporeal membrane oxygenation (ECMO) should be considered within the pandemic to support patients with severe COVID-19 related acute hypoxemic respiratory failure that is refractory to lung-protective mechanical ventilation (Barbaro, et al. 2020). Based on their analysis, it has been recommended the use of ECMO to be reserved for the most critically ill SARS-Cov-2 (COVID-19) patients who fit criteria for this specialized therapy in expert centers proficient in ECMO management. However, there is question as to the effectiveness of ECMO support regarding mortality rates in COVID-19 patients, which have been estimated to be anywhere from 19.83% to 83.33% (Haduic, et al. 2020). Further examination into the factors that predict either survival or mortality for this patient population receiving ECMO therapy have been reported in the literature (Savarimuthu, et al., 2020). Yet, a gap in the literature exists in investigating if renal dysfunction is a predictor of mortality in patients on VV ECMO for severe ARDS related to the COVID-19 infection.

Language

English

Share

COinS